Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Pulmonology
•
Diffuse Parenchymal Lung Disease
•
IPF
How do you counsel patients regarding prognosis following a diagnosis of IPF?
Related Questions
Would you consider using steroids in patients with respiratory failure caused by aspiration pneumonitis?
Do you seek pathologic confirmation before proceeding with empiric immunosuppressive therapy in symptomatic patients with radiographic NSIP?
How do you manage pleuroparenchymal fibroelastosis in a patient with seronegative RA that is progressing on Rituxan and DMARD therapy?
How would you approach management of a patient with seropositive RA and UIP-ILD, with concern for active lung disease?
What is your approach to managing ILD associated with inflammatory bowel disease?
How long after initiating mycophenolate do you wait before tapering prednisone off in patients with myositis-associated ILD?
What is your approach to evaluating amiodarone induced interstitial pneumonitis?
What are your thoughts on using abatacept for RA-associated ILD in a patient undergoing treatment for CLL with zanubrutinib, and how would you assess the potential increased risk of infection in this context?
Do you always stop dexamethasone at discharge for patients admitted with COVID requiring respiratory support (as done in the RECOVERY trial), or are there situations in which you will prescribe it to complete a 10-day course?
Would you biopsy calcified lung nodules and or lymphadenopathy that have shown stability over a 2-year period, in a bid to rule out sarcoidosis?
